{
    "nct_id": "NCT06225011",
    "official_title": "Repurposing Drugs as Immunotherapeutic Agents: Changes in Colorectal Tumor Immune Cells After Targeting Serotonin",
    "inclusion_criteria": "* Male or female ≥ 18 years of age at visit 1\n* Previously untreated cytologically or histologically confirmed colorectal adenocarcinoma that will not need neoadjuvant therapy\n* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study\n* World Health Organization (WHO) Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Absolute neutrophil count (ANC) ≥ 1.5x10^9/L\n* Platelets ≥ 100x10^9/L\n* Hemoglobin ≥ 9 g/dL\n* Serum creatinine (sCr) ≤ 1.5 x upper limit of normal (ULN)\n* Creatinine clearance (Ccr) ≥ 40 mL/min (as calculated by Modified Cockcroft-Gault formula)\n* Serum total bilirubin ≤ 1.5 x ULN\n* Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 x ULN\n* Baseline corrected QT (QTc) within normal limits per the Bazett formula. Any electrocardiogram (EKG) done prior to consent is acceptable for baseline QTc monitoring.\n\n  * Normal QTc ranges from 350-450 ms for adult men and from 360-460 ms for adult women\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the participant or the quality of the data\n* A diagnosis of metastatic colorectal adenocarcinoma\n* Individuals who have received neoadjuvant chemotherapy prior to the planned colon cancer resection\n* Individuals with absolute or relative contraindications to fluoxetine\n\n  * Baseline prolonged QTc\n  * Concurrently taking tamoxifen, pimozide, or thioridazine\n* Individuals using other SSRIs, serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), lithium or other antidepressants at time of initial biopsy\n* Currently active second primary malignancy or history of malignancy less than 5 years prior to the time of study eligibility (Patients with history of skin cancers excluding melanoma will be eligible for participation)",
    "miscellaneous_criteria": ""
}